{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:33:58Z","timestamp":1794047638387,"version":"4.8.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.blre.2024.101195","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T04:29:38Z","timestamp":1710995378000},"page":"101195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["BCL-2 inhibition in haematological malignancies: Clinical application and complications"],"prefix":"10.1016","volume":"65","author":[{"given":"Dominic J.","family":"Fowler-Shorten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Markham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian M.","family":"Bowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Rushworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2024.101195_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.biochem.69.1.217","article-title":"Apoptosis signaling","volume":"69","author":"Strasser","year":"2000","journal-title":"Annu Rev Biochem"},{"issue":"14","key":"10.1016\/j.blre.2024.101195_bb0010","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.1074\/jbc.270.14.7795","article-title":"A novel protein that interacts with the death domain of Fas\/APO1 contains a sequence motif related to the death domain","volume":"270","author":"Boldin","year":"1995","journal-title":"J Biol Chem"},{"issue":"7232","key":"10.1016\/j.blre.2024.101195_bb0015","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/nature07606","article-title":"The Fas-FADD death domain complex structure unravels signalling by receptor clustering","volume":"457","author":"Scott","year":"2009","journal-title":"Nature"},{"issue":"Pt 1","key":"10.1016\/j.blre.2024.101195_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3260001","article-title":"Caspases: the executioners of apoptosis","volume":"326","author":"Cohen","year":"1997","journal-title":"Biochem J"},{"issue":"4706","key":"10.1016\/j.blre.2024.101195_bb0025","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"issue":"6189","key":"10.1016\/j.blre.2024.101195_bb0030","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"issue":"4656","key":"10.1016\/j.blre.2024.101195_bb0035","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1126\/science.6610211","article-title":"Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation","volume":"224","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0092-8674(86)90362-4","article-title":"Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2\/immunoglobulin transcript resulting from the t(14;18) translocation","volume":"47","author":"Cleary","year":"1986","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0045","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson","year":"1996","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0050","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2024.101195_bb0055","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2024.101195_bb0060","first-page":"5501","article-title":"Immunohistochemical analysis of in vivo patterns of Bcl-X expression","volume":"54","author":"Krajewski","year":"1994","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0065","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1084\/jem.191.6.977","article-title":"Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL","volume":"191","author":"Horita","year":"2000","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.blre.2024.101195_bb0070","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuilleme-Toumi","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2024.101195_bb0075","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/blood-2004-05-1760","article-title":"VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis","volume":"104","author":"Le Gouill","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0080","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1172\/JCI39964","article-title":"Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia","volume":"120","author":"Xiang","year":"2010","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"10.1016\/j.blre.2024.101195_bb0090","first-page":"1921","article-title":"Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins","volume":"11","author":"Boyd","year":"1995","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","article-title":"Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics","volume":"2","author":"Letai","year":"2002","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1074\/jbc.M113.505701","article-title":"Evaluation of the BH3-only protein Puma as a direct Bak activator","volume":"289","author":"Dai","year":"2014","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0105","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molcel.2013.08.048","article-title":"BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response","volume":"51","author":"Sarosiek","year":"2013","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/excr.2000.4838","article-title":"Induction of apoptosis by cancer chemotherapy","volume":"256","author":"Kaufmann","year":"2000","journal-title":"Exp Cell Res"},{"issue":"4","key":"10.1016\/j.blre.2024.101195_bb0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13277-010-0042-8","article-title":"Radiation-induced cell death mechanisms","volume":"31","author":"Eriksson","year":"2010","journal-title":"Tumour Biol"},{"issue":"24","key":"10.1016\/j.blre.2024.101195_bb0120","doi-asserted-by":"crossref","first-page":"11867","DOI":"10.1158\/0008-5472.CAN-07-1961","article-title":"Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion","volume":"67","author":"Deng","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.blre.2024.101195_bb0125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0092-8674(95)90071-3","article-title":"FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis","volume":"81","author":"Chinnaiyan","year":"1995","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.blre.2024.101195_bb0130","doi-asserted-by":"crossref","first-page":"11843","DOI":"10.1074\/jbc.M115.711051","article-title":"Cleavage by caspase 8 and mitochondrial membrane association activate the BH3-only protein bid during TRAIL-induced apoptosis","volume":"291","author":"Huang","year":"2016","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0135","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.cell.2008.11.010","article-title":"Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax","volume":"135","author":"Lovell","year":"2008","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.blre.2024.101195_bb0140","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1101\/gad.14.16.2060","article-title":"tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c","volume":"14","author":"Wei","year":"2000","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0145","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1128\/MCB.20.3.929-935.2000","article-title":"Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane","volume":"20","author":"Eskes","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer\u2019s addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0155","first-page":"98","article-title":"Bcl-2 oncoprotein expression in acute myeloid leukemia","volume":"80","author":"Bensi","year":"1995","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0160","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.leukres.2009.05.009","article-title":"BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients","volume":"34","author":"Moon","year":"2010","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/156800908784293640","article-title":"Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia","volume":"8","author":"Del Poeta","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"issue":"39","key":"10.1016\/j.blre.2024.101195_bb0170","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"10.1016\/j.blre.2024.101195_bb0175","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1002\/cncr.27568","article-title":"Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment","volume":"118","author":"Quintas-Cardama","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0180","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1016\/j.blre.2024.101195_bb0185","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.leu.2401302","article-title":"Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy","volume":"13","author":"Puthier","year":"1999","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0195","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor-1 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0200","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.blre.2024.101195_bb0205","doi-asserted-by":"crossref","first-page":"9485","DOI":"10.1021\/bi025605h","article-title":"Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death","volume":"41","author":"Shangary","year":"2002","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0210","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41418-018-0183-7","article-title":"BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X(L)","volume":"26","author":"Greaves","year":"2019","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","author":"Chen","year":"2005","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.blre.2024.101195_bb0220","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.molcel.2005.02.003","article-title":"BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly","volume":"17","author":"Kuwana","year":"2005","journal-title":"Mol Cell"},{"issue":"7042","key":"10.1016\/j.blre.2024.101195_bb0225","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.blre.2024.101195_bb0230","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0235","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.blre.2024.101195_bb0240","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/cdd.2008.25","article-title":"A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells","volume":"15","author":"Vogler","year":"2008","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0245","first-page":"79","article-title":"The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells","volume":"3","author":"Baev","year":"2014","journal-title":"Leuk Res Rep"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0250","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Del Gaizo","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.blre.2024.101195_bb0255","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.blre.2024.101195_bb0260","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.blre.2024.101195_bb0265","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2014-09-601567","article-title":"MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice","volume":"124","author":"Grabow","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2024.101195_bb0270","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","article-title":"Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1","volume":"115","author":"Yecies","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2024.101195_bb0275","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2024.101195_bb0280","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0285","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101195_bb0290","series-title":"Results from a phase 2 study of Navitoclax in combination with Ruxolitinib in patients with primary or secondary myelofibrosis","author":"Claire","year":"2019"},{"key":"10.1016\/j.blre.2024.101195_bb0295","first-page":"142","article-title":"Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of Navitoclax in combination with Ruxolitinib versus Ruxolitinib plus placebo in patients with untreated myelofibrosis","author":"Naveen Pemmaraju","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101195_bb0300","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2021-149530","article-title":"Dual BCL-2\/BCL-XL inhibitor Pelcitoclax (APG-1252) overcomes intrinsic and acquired resistance to Venetoclax in multiple myeloma cells","volume":"138","author":"Yamamoto","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0305","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3892\/ijo.2017.4028","article-title":"APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2\/Bcl-xl in HL-60 cells","volume":"51","author":"Wang","year":"2017","journal-title":"Int J Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101195_bb0310","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.1182\/blood-2022-167372","article-title":"LP-118, a novel BCL2 inhibitor, shows potent in vitro anti-myeloma activity","volume":"140","author":"Fonseca","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101195_bb0315","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-151852","article-title":"Characterization of LP-118, a novel small molecule inhibitor of Bcl-2 and Bcl-xl in chronic lymphocytic leukemia resistant to Venetoclax","volume":"138","author":"Ravikrishnan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101195_bb0320","series-title":"Study of oral administration of LP-118 in patients with relapsed or refractory CLL, SLL, MDS, MDS\/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL, Identifier: NCT04771572","year":"2023"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0325","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12457","article-title":"ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets","volume":"163","author":"Vogler","year":"2013","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.blre.2024.101195_bb0330","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0335","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to Venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.blre.2024.101195_bb0340","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0345","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0350","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0355","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2024.101195_bb0360","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL forestalls the Acquisition of Resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.blre.2024.101195_bb0365","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1158\/1078-0432.CCR-15-3057","article-title":"Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with Daunorubicin or Cytarabine in AML cells","volume":"22","author":"Niu","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2024.101195_bb0370","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of Venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.blre.2024.101195_bb0375","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0380","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.blre.2024.101195_bb0385","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101195_bb0390","author":"Administration USFaD"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0395","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.blre.2024.101195_bb0400","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.blre.2024.101195_bb0410","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0415","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0420","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2024.101195_bb0425","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0430","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5492\/wjccm.v4.i2.130","article-title":"Tumor lysis syndrome: a clinical review","volume":"4","author":"Mirrakhimov","year":"2015","journal-title":"World J Crit Care Med"},{"issue":"24","key":"10.1016\/j.blre.2024.101195_bb0435","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2024.101195_bb0440","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","article-title":"6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141\/150)","volume":"11","author":"Wei","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.blre.2024.101195_bb0445","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.18369","article-title":"Management of older patients with frailty and acute myeloid leukaemia: a British Society for Haematology good practice paper","volume":"199","author":"Dennis","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0450","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000912","article-title":"BCL2 inhibition: a new paradigm for the treatment of AML and beyond","volume":"7","author":"Wei","year":"2023","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101195_bb0455","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2022-165464","article-title":"Reduced Venetoclax exposition to seven days of Azacitidine is efficient in treatment-Na\u00efve patients with acute myeloid leukemia","volume":"140","author":"Willekens","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101195_bb0460","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1182\/blood-2022-170059","article-title":"A non-cytotoxic regimen using a weekly low dose Decitabine and Venetoclax for MDS and AML in a real world cohort","volume":"140","author":"Levitz","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2024.101195_bb0465","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: from discovery to translation","volume":"288","author":"Kirkland","year":"2020","journal-title":"J Intern Med"},{"issue":"24","key":"10.1016\/j.blre.2024.101195_bb0470","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Quintas-Cardama","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0475","first-page":"101","article-title":"Long-term bone marrow damage in experimental systems and in patients after radiation or chemotherapy","volume":"5","author":"Testa","year":"1985","journal-title":"Anticancer Res"},{"key":"10.1016\/j.blre.2024.101195_bb0480","series-title":"Hematopoiesis: long-term effects of chemotherapy and radiation","first-page":"63","article-title":"Myelosuppressive effects of antineoplastic chemotherapy","author":"Gale","year":"1988"},{"key":"10.1016\/j.blre.2024.101195_bb0485","series-title":"Hematopoiesis: Long-term effects of chemotherapy and radiation","first-page":"325","article-title":"Long-term hematopoietic damage after cytotoxic drug therapy for solid tumours","author":"WS","year":"1988"},{"issue":"4","key":"10.1016\/j.blre.2024.101195_bb0490","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.V72.4.1193.1193","article-title":"Permanent loss in stem cell self renewal capacity following stress to the marrow","volume":"72","author":"Mauch","year":"1988","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2024.101195_bb0495","first-page":"5414","article-title":"Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells","volume":"63","author":"Meng","year":"2003","journal-title":"Cancer Res"},{"issue":"20","key":"10.1016\/j.blre.2024.101195_bb0500","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1182\/blood-2013-07-515619","article-title":"Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an Ink4a- and Arf-independent manner","volume":"123","author":"Shao","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101195_bb0505","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283944","article-title":"Acute myeloid leukemia driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias","author":"Fowler-Shorten","year":"2024","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2024.101195_bb0510","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1016\/S2152-2650(23)00461-5","volume":"23","author":"Fathi","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.blre.2024.101195_bb0515","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"Daver","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0520","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr Cancer Ther Rev"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0525","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2024.101195_bb0530","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.26269","article-title":"Venetoclax for the treatment of multiple myeloma: outcomes outside of clinical trials","volume":"96","author":"Sidiqi","year":"2021","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.blre.2024.101195_bb0535","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2024.101195_bb0540","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.blre.2024.101195_bb0545","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2024.101195_bb0550","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/10428194.2019.1709835","article-title":"A single-center retrospective cohort analysis of venetoclax in relapsed\/refractory multiple myeloma","volume":"61","author":"Kambhampati","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2024.101195_bb0555","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"issue":"28","key":"10.1016\/j.blre.2024.101195_bb0560","doi-asserted-by":"crossref","first-page":"20075","DOI":"10.18632\/oncotarget.24744","article-title":"S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth","volume":"9","author":"Casara","year":"2018","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.blre.2024.101195_bb0565","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2024.101195_bb0570","series-title":"Study of APG-2575 in patients with relapsed\/refractory CLL\/SLL, Identifier: NCT05147467","year":"2023"},{"key":"10.1016\/j.blre.2024.101195_bb0575","series-title":"APG-2575 in combination with novel therapeutic regimens in subjects with relapsed or refractory multiple myeloma, identifier: NCT04942067","year":"2023"},{"issue":"23","key":"10.1016\/j.blre.2024.101195_bb0580","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101195_bb0585","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3389\/fonc.2018.00458","article-title":"Hematologic tumor cell resistance to the BCL-2 inhibitor Venetoclax: a product of its microenvironment?","volume":"8","author":"Leverson","year":"2018","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.blre.2024.101195_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.blre.2024.101195_bb0595","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood.2020008194","article-title":"BCL-2 inhibition in follicular lymphoma: can we tip the scales?","volume":"136","author":"Fowler","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0600","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40164-023-00424-z","article-title":"Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting","volume":"12","author":"Gong","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2024.101195_bb0605","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2024.101195_bb0610","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.13581","article-title":"Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia","volume":"293","author":"Weng","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.blre.2024.101195_bb0615","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","article-title":"Small molecule Mcl-1 inhibitors for the treatment of cancer","volume":"145","author":"Belmar","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.blre.2024.101195_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0625","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"13","key":"10.1016\/j.blre.2024.101195_bb0630","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"issue":"7626","key":"10.1016\/j.blre.2024.101195_bb0635","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.blre.2024.101195_bb0640","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood-2018-06-859405","article-title":"Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use","volume":"132","author":"Brennan","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2024.101195_bb0645","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41420-022-01211-1","article-title":"BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia","volume":"8","author":"Parry","year":"2022","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.blre.2024.101195_bb0650","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2024.101195_bb0655","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/jphp.13240","article-title":"Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma","volume":"72","author":"Wong","year":"2020","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.blre.2024.101195_bb0660","series-title":"AACR annual meeting 2021","article-title":"Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1","author":"Bhagwat","year":"2021"},{"key":"10.1016\/j.blre.2024.101195_bb0665","series-title":"AACR annual meeting 2023","article-title":"A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced\/metastatic solid tumors","author":"Falchook","year":"2023"},{"key":"10.1016\/j.blre.2024.101195_bb0670","series-title":"A study of PRT1419 in patients with relapsed\/refractory hematologic malignancies","year":"2023"},{"issue":"14","key":"10.1016\/j.blre.2024.101195_bb0675","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-19-1397","article-title":"AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia","volume":"26","author":"Yi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.blre.2024.101195_bb0680","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic Cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2024.101195_bb0685","series-title":"AMG 176 first in human trial in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia, identifier: NCT02675452","year":"2023"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T11:27:51Z","timestamp":1713353271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":137,"alternative-id":["S0268960X24000286"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101195","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCL-2 inhibition in haematological malignancies: Clinical application and complications","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101195"}}